Healthcare IT News

Auto-Injectors Market Latest Innovations, Drivers, Dynamics And Strategic Analysis, Challenges

Press Release

In terms of therapeutic application, the auto-injectors market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The other applications include migraine, psoriasis and diabetes. Among the therapeutic application, the anaphylaxis segmented contributed to almost 88% of the overall market for auto-injectors in 2016. Some of the major factors driving the growth of this application include, increasing prevalence of anaphylaxis globally and rising awareness about the auto-injectors for treating various allergies effectively.

Request to Get the Sample Pages at:

Healthcare spending by patients is concurrently increasing globally, due to the rising prevalence of chronic diseases, continuous rise of aging population and increasing healthcare expenditure by the government. Increasing prevalence of some of the chronic diseases such as diabetes, heart diseases and mental illness has led to an increase in the overall healthcare spending in developed and emerging economies. In developed countries, the disposable income is high leading to added affordability on the patient’s end who can spend on advanced healthcare facilities.

Make Enquiry Before Buying the Report:

The auto-injectors market in Europe is expected to reach $537.2 million by 2023, growing at a CAGR of 17.4% between 2017-2023. The auto-injectors industry in Europe is witnessing growth mainly due to increasing prevalence of diseases such as anaphylaxis, multiple sclerosis, diabetes and rising geriatric population. According to European Academy of Allergy and Clinical Immunology, more than 150 million Europeans suffered from chronic allergy diseases in 2016. Among the various countries in the European region, the U.K. held the largest share of the European market for auto-injectors with 29.1% share in 2016.

Some of the key players operating in the auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.